315 related articles for article (PubMed ID: 33324983)
1. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
3. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
[TBL] [Abstract][Full Text] [Related]
5. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
[TBL] [Abstract][Full Text] [Related]
6. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
8. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.
Takagi T; Kondo T; Kennoki T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Jpn J Clin Oncol; 2013 Apr; 43(4):439-43. PubMed ID: 23303839
[TBL] [Abstract][Full Text] [Related]
10. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
[TBL] [Abstract][Full Text] [Related]
11. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
12. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
13. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
[TBL] [Abstract][Full Text] [Related]
14. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
Ishihara H; Fukuda H; Takagi T; Kondo T; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
Int J Urol; 2021 Jan; 28(1):99-106. PubMed ID: 33159426
[TBL] [Abstract][Full Text] [Related]
16. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
[TBL] [Abstract][Full Text] [Related]
17. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.
Harada K; Nozawa M; Uemura M; Tatsugami K; Osawa T; Yamana K; Kimura G; Fujisawa M; Nonomura N; Eto M; Shinohara N; Tomita Y; Kondo Y; Ochi K; Anazawa Y; Uemura H
Int J Urol; 2019 Feb; 26(2):202-210. PubMed ID: 30345560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
